ONCT 0.75 (+5.63%)
US68236P1075BiotechnologyBiotechnology

Oncternal Therapeutics (ONCT) Stock Highlights

0.75 | +5.63%
2024-11-27 06:51:31
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Companys clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Statistics

Range Today
0.71 0.8
Volume Today 754.7K
Range 1 Year
0.62 13.2
Volume 1 Year 9.14M
Range 3 Year
0.62 62.4
Volume 3 Year 20.35M
Range 10 Year
0.62 3584
Volume 10 Year 52.08M

Highlights

Market Capitalization 3.76M (micro)
Floating Shares 2.71M
Current Price 0.75
Price To Earnings -0.12
Price To Revenue -4.92
Price To Book 0.41
Earnings Per Share -11.29
Payout Ratio 0%

Performance

Latest +5.63%
1 Month -49.66%
3 Months -84.91%
6 Months -92.09%
1 Year -90.13%
3 Years -98.77%
5 Years -99.38%
10 Years -99.92%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.